Clinical trial
Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With…
NCT00078325 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00078325 |
|---|---|
| Title | Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS) |
| Official title | A 12 Week, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CEP 10953 (150 and 250 mg/Day) as Treatment for Adults With Residual Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Obstructive Sleep Apnea, Hypopnea |
| Intervention type | Drug |
| Interventions | Armodafinil 250 mg/day, Armodafinil 150 mg/day, Placebo |
| Enrollment | 395 |
| Start date | Feb 1, 2004 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Feb 25, 2004 |
| Last update posted | Jul 19, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: